Table 4.
Stratified analyses of 90‐day mRS between heparin and standard ATT groups in the matched population
| Subgroup | No. of patients | Early IVH group | Standard ATT group |
Common OR a (95% CI) |
P for interaction |
|---|---|---|---|---|---|
| mRS at 90 days, median (IQR) | |||||
| Age | 0.70 | ||||
| ≤ 60 years | 171 | 2 (1–3) | 3 (1–4) | 1.82 (1.01–3.25) | |
| > 60 years | 180 | 2 (1–4) | 3 (1–5) | 2.16 (1.15–4.06) | |
| Sex | 0.31 | ||||
| Male | 254 | 2 (1–4) | 3 (1–4) | 1.72 (1.03–2.86) | |
| Female | 97 | 3 (0–4) | 4 (1–5) | 2.80 (1.21–6.49) | |
| Atrial fibrillation | 0.49 | ||||
| Yes | 41 | 2 (1–3) | 4 (1–6) | 2.97 (0.79–11.36) | |
| No | 310 | 2 (1–4) | 3 (1–4) | 1.86 (1.16–2.94) | |
| Admission NIHSS score | 0.12 | ||||
| < 15 points | 185 | 1 (0–3) | 2 (1–3) | 1.42 (0.87–2.32) | |
| ≥ 15 points | 166 | 3 (1–4) | 4 (3–6) | 2.64 (1.40–5.00) | |
| Onset‐to‐needle time | 0.25 | ||||
| ≤ 3 hr | 142 | 2 (0–4) | 3 (1–5) | 2.75 (1.20–6.30) | |
| > 3 hr | 209 | 2 (1–4) | 3 (1–4) | 1.57 (0.93–2.64) | |
| tPA dose | 0.28 | ||||
| Full dose (0.9mg/kg, max = 90mg) | 211 | 2 (1–4) | 3 (1–4) | 1.62 (0.90–2.86) | |
| Low dose (0.5–0.8mg/kg, max = 50mg) | 140 | 2 (0–3) | 3 (1–5) | 2.64 (1.36–5.10) | |
| Stroke territory | 0.65 | ||||
| Anterior circulation | 201 | 2 (1–3) | 3 (1–4) | 1.79 (1.08–2.97) | |
| Posterior circulation | 150 | 2 (0–4) | 3 (1–6) | 2.18 (1.02–4.66) | |
| Stroke subtype | 0.66 | ||||
| Large artery atherosclerosis | 222 | 2 (1–4) | 3 (1–5) | 1.99 (1.14–3.49) | |
| Non‐large artery atherosclerosis | 129 | 2 (0–3) | 2 (1–4) | 1.65 (0.84–3.22) | |
Abbreviations: ATT, antithrombotic therapy, CI, confidence interval, IQR, interquartile range, IVH, intravenous heparin, mRS, modified Rankin Scale, NIHSS, National Institutes of Health Stroke Scale, TOAST, Trial of Org 10,172 in Acute Stroke Treatment, tPA, tissue Plasminogen Activator.
a
The common OR values were calculated using an ordinal logistic regression model and indicated the odds of improvement of 1 point on the mRS at 90 days.